Search Results - "Cella, David F"

Correlation Between the International Consensus Definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and Patient-Centered Outcomes in Advanced Non-Small Cell Lung Cancer by LeBlanc, Thomas W., MD, MA, Nipp, Ryan D., MD, Rushing, Christel N., MA, Samsa, Greg P., PhD, Locke, Susan C., PhD, Kamal, Arif H., MD, Cella, David F., PhD, Abernethy, Amy P., MD, PhD

“…Abstract Context The cancer anorexia-cachexia syndrome (CACS) is common in patients with advanced solid tumors and is associated with adverse outcomes…”
Get full text

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update by RIZZO, J. Douglas, SOMERFIELD, Mark R, RARICK, Mark U, REGAN, David H, LICHTIN, Alan E, HAGERTY, Karen L, SEIDENFELD, Jerome, BOHLIUS, Julia, BENNETT, Charles L, CELLA, David F, DJULBEGOVIC, Benjamin, GOODE, Matthew J, JAKUBOWSKI, Ann A

“…To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was…”
Get full text

Long-Term Health-Related Quality of Life, Growth, and Spiritual Well-Being After Hematopoietic Stem-Cell Transplantation by ANDRYKOWSKI, Michael A, BISHOP, Michelle M, HAHN, Elizabeth A, CELLA, David F, BEAUMONT, Jennifer L, BRADY, Marianne J, HOROWITZ, Mary M, SOBOCINSKI, Kathleen A, RIZZO, J. Douglas, WINGARD, John R

“…To examine health-related quality of life (HRQOL) and growth, and spiritual well-being in adult survivors of hematopoietic stem-cell transplantation (HSCT) for…”
Get full text

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group by MOORE, David H, DONNELLY, James, MCGUIRE, William P, ALMADRONES, Lois, CELLA, David F, HERZOG, Thomas J, WAGGONER, Steven E

“…The purpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically significant (grade 2 to 4) neurotoxicity associated…”
Get full text

Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS® Global Health, CDC Healthy Days, and satisfaction with life instruments by Barile, John P., Reeve, Bryce B., Smith, Ashley Wilder, Zack, Matthew M., Mitchell, Sandra A., Kobau, Rosemarie, Cella, David F., Luncheon, Cecily, Thompson, William W.

“…Purpose Healthy People 2020 identified health-related quality of life and well-being (WB) as indicators of population health for the next decade. This study…”
Get full text

Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS) by LeBlanc, Thomas W., Samsa, Greg P., Wolf, Steven P., Locke, Susan C., Cella, David F., Abernethy, Amy P.

“…Purpose Patients with cancer anorexia-cachexia syndrome (CACS) suffer a significant symptom burden, impaired quality of life (QoL), and shorter survival…”
Get full text

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update by Rizzo, J. Douglas, Somerfield, Mark R., Hagerty, Karen L., Seidenfeld, Jerome, Bohlius, Julia, Bennett, Charles L., Cella, David F., Djulbegovic, Benjamin, Goode, Matthew J., Jakubowski, Ann A., Rarick, Mark U., Regan, David H., Lichtin, Alan E.

“…Purpose: To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline…”
Get full text

Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort by Castel, Liana D., Hartmann, Katherine E., Mayer, Ingrid A., Saville, Benjamin R., Alvarez, JoAnn, Boomershine, Chad S., Abramson, Vandana G., Chakravarthy, A. Bapsi, Friedman, Debra L., Cella, David F.

“…BACKGROUND More than 80,000 postmenopausal breast cancer patients in the United States each year are estimated to begin a 5‐year course of aromatase inhibitors…”
Get full text

Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G by King, Madeleine T, Stockler, Martin R, Cella, David F, Osoba, David, Eton, David T, Thompson, Joanna, Eisenstein, Amy R

“…Abstract Objective To compare Cohen's guidelines for small (0.2), medium (0.5), and large (0.8) effect sizes with empirical estimates for a cancer-specific…”
Get full text

Effect of Computer Support on Younger Women with Breast Cancer by Gustafson, David H., Hawkins, Robert, Pingree, Suzanne, McTavish, Fiona, Arora, Neeraj K., Mendenhall, John, Cella, David F., Serlin, Ronald C., Apantaku, Funmi M., Stewart, James, Salner, Andrew

“…OBJECTIVE: Assess impact of a computer‐based patient support system on quality of life in younger women with breast cancer, with particular emphasis on…”
Get full text

Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study by ARORA, Neeraj K, GUSTAFSON, David H, HAWKINS, Robert P, MCTAVISH, Fiona, CELLA, David F, PINGREE, Suzanne, MENDENHALL, John H, MAHVI, David M

“…Studies that prospectively and simultaneously evaluate, within the first year of diagnosis, the impact of surgery and chemotherapy on quality of life (QOL) of…”
Get full text

Improving Health-Related Quality of Life in Non–Small-Cell Lung Cancer with Current Treatment Options by Cella, David F, Patel, Jyoti D

“…Abstract Non–small-cell lung cancer (NSCLC) accounts for > 80% of all lung carcinomas, with the majority of patients presenting with late-stage disease…”
Get full text

The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity by List, Marcy A., D'Antonio, Linda L., Cella, David F., Siston, Amy, Mumby, Patricia, Haraf, Daniel, Vokes, Everett

“…BACKGROUND The goal of this investigation was to examine the relationship between, and application of, two disease specific quality of life (QL) measures…”
Get full text

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument by Cella, David F., Bonomi, Amy E., Lloyd, Stephen R., Tulsky, David S., Kaplan, Edward, Bonomi, Philip

“…The FACT-L (version 3) is a 44-item self-report instrument which measures multidimensional quality of life. Available in eight languages, it is currently being…”
Get full text

Age and clinical decision making in oncology patients by Yellen, S B, Cella, D F, Leslie, W T

“…Ageism is a cultural bias that might inappropriately steer oncologists away from recommending aggressive treatments for older patients. The extent to which…”
Get more information

Death anxiety in cancer survival: a preliminary cross-validation study by Cella, D F, Tross, S

“…In an attempt to cross-validate the results with cancer survivors and to test its sensitivity to illness-related variables, the Death Anxiety Questionnaire…”
Get more information

Psychological Adjustment to Survival From Hodgkin's Disease by Cella, David F, Tross, Susan

“…This study is presented as a model for studying the psychosocial sequelae of successful cancer treatment. It compares the psychological adjustment of 60 male…”
Get full text

The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure by Cella, D F, Tulsky, D S, Gray, G, Sarafian, B, Linn, E, Bonomi, A, Silberman, M, Yellen, S B, Winicour, P, Brannon, J

“…We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment,…”
Get full text

Quality of life: the concept by Cella, D F

Get more information

The Influence of Stress Management Training In HIV Disease by McCain, Nancy L, Zeller, Janice M, Cella, David F, Urbanski, Pamela A, Novak, Richard M

“…A pretest-posttest design (with a 6-week wait-list control and a 6-month comparison group) was used to compare the effectiveness of a 6-week stress management…”
Get full text